Joseph S Dillon
Overview
Explore the profile of Joseph S Dillon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jimenez C, Chin B, Noto R, Dillon J, Solnes L, Stambler N, et al.
Endocr Relat Cancer
. 2022 Dec;
30(2).
PMID: 36472300
The objective of this study is to present the complete biomarker response dataset from a pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 meta-iodobenzylguanidine in patients with advanced...
12.
Ziogas I, Tasoudis P, Borbon L, Sherman S, Breheny P, Chandrasekharan C, et al.
Ann Surg Oncol
. 2022 Oct;
30(1):148-160.
PMID: 36227392
Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare, aggressive tumors with poor prognosis. The World Health Organization 2017 and 2019 classifications further subdivided G3 NENs into G3...
13.
Ziogas I, Dillon J, Chandrasekharan C, Howe J
Ann Surg Oncol
. 2022 Oct;
30(1):161-162.
PMID: 36209329
No abstract available.
14.
Borbon L, Tran C, Sherman S, Ear P, Chandrasekharan C, Bellizzi A, et al.
Ann Surg Oncol
. 2022 Jul;
29(11):6936-6946.
PMID: 35802214
Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are aggressive tumors with poor survival outcomes for which medical management is generally recommended. This study sought to evaluate outcomes of...
15.
Tran C, Sherman S, Suraju M, Nayyar A, Gerke H, El Abiad R, et al.
Ann Surg Oncol
. 2021 Sep;
29(1):75-84.
PMID: 34515889
Background: Management of duodenal neuroendocrine tumors (DNETs) is not standardized, with smaller lesions (< 1-2 cm) generally treated by endoscopic mucosal resection (EMR) and larger DNETs by surgical resection (SR)....
16.
Jha A, Taieb D, Carrasquillo J, Pryma D, Patel M, Millo C, et al.
Clin Cancer Res
. 2021 Mar;
27(11):2989-2995.
PMID: 33685867
Targeted radionuclide therapies (TRT) using I-metaiodobenzylguanidine (I-MIBG) and peptide receptor radionuclide therapy (Lu or Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-I-MIBG therapy...
17.
Scott A, Tessmann J, Braun T, Brown B, Breheny P, Darbro B, et al.
Am J Med Genet A
. 2021 Mar;
185(5):1582-1588.
PMID: 33650152
Currarino syndrome (CS) is an autosomal dominant syndrome caused by mutations in MNX1 and characterized by anorectal abnormalities, partial sacral agenesis, and presacral masses. The presacral masses are typically benign;...
18.
Dillon J, Bushnell D, Laux D
Future Oncol
. 2021 Jan;
17(10):1131-1141.
PMID: 33506713
Pheochromocytomas and paragangliomas (PPG) are rare cancers arising from the adrenal medulla (pheochromocytoma) or autonomic ganglia (paraganglioma). They have highly variable biological behavior. Most PPG express high-affinity norepinephrine transporters, allowing...
19.
Tran C, Sherman S, Scott A, Ear P, Chandrasekharan C, Bellizzi A, et al.
Ann Surg Oncol
. 2020 Jul;
28(2):732-741.
PMID: 32656719
Background: Tumor biomarkers (TBMs) reflect disease burden and correlate with survival for small bowel neuroendocrine tumors (SBNETs). This study sought to determine the performance of chromogranin A (CgA), pancreastatin (PST),...
20.
Bergsland E, Halperin D, Dillon J, Dasari N, Kunz P, Soares H, et al.
Pancreas
. 2020 May;
49(6):723-728.
PMID: 32433264
No abstract available.